146 related articles for article (PubMed ID: 37295906)
1. Reply to the Letter to the Editor 'Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to "Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up")' by Cellini et al.
Obermannová R; Smyth EC;
Ann Oncol; 2023 Jun; 34(6):554-555. PubMed ID: 37295906
[No Abstract] [Full Text] [Related]
2. Neoadjuvant radiochemotherapy and perioperative chemotherapy do not represent a standard at the same priority level for esophageal adenocarcinomas (with regard to 'Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up').
Cellini F; Manfrida S; Gambacorta MA; Valentini V
Ann Oncol; 2023 Jun; 34(6):553-554. PubMed ID: 36965575
[No Abstract] [Full Text] [Related]
3. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.
van der Kaaij RT; Snaebjornsson P; Voncken FE; van Dieren JM; Jansen EP; Sikorska K; Cats A; van Sandick JW
Eur J Cancer; 2017 May; 76():27-35. PubMed ID: 28262585
[TBL] [Abstract][Full Text] [Related]
6. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant treatment of oesophageal adenocarcinoma.
Robb WB; Naughton P; Walsh TN
Minerva Chir; 2004 Oct; 59(5):461-70. PubMed ID: 15494673
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
9. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
10. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
[TBL] [Abstract][Full Text] [Related]
11. [Non-metastatic oesophageal cancer: diagnosis and treatment].
Voeten DM; den Bakker CM; Goedegebuure RSA; Heineman DJ; Daams F; van der Peet DL
Ned Tijdschr Geneeskd; 2019 Sep; 163():. PubMed ID: 31556490
[TBL] [Abstract][Full Text] [Related]
12. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
Sjoquist KM; Burmeister BH; Smithers BM; Zalcberg JR; Simes RJ; Barbour A; Gebski V;
Lancet Oncol; 2011 Jul; 12(7):681-92. PubMed ID: 21684205
[TBL] [Abstract][Full Text] [Related]
13. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
14. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer.
Veuillez V; Rougier P; Seitz JF
Best Pract Res Clin Gastroenterol; 2007; 21(6):947-63. PubMed ID: 18070697
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).
van Heijl M; van Lanschot JJ; Koppert LB; van Berge Henegouwen MI; Muller K; Steyerberg EW; van Dekken H; Wijnhoven BP; Tilanus HW; Richel DJ; Busch OR; Bartelsman JF; Koning CC; Offerhaus GJ; van der Gaast A
BMC Surg; 2008 Nov; 8():21. PubMed ID: 19036143
[TBL] [Abstract][Full Text] [Related]
16. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
Moehler M; Baltin CT; Ebert M; Fischbach W; Gockel I; Grenacher L; Hölscher AH; Lordick F; Malfertheiner P; Messmann H; Meyer HJ; Palmqvist A; Röcken C; Schuhmacher C; Stahl M; Stuschke M; Vieth M; Wittekind C; Wagner D; Mönig SP
Gastric Cancer; 2015 Jul; 18(3):550-63. PubMed ID: 25192931
[TBL] [Abstract][Full Text] [Related]
17. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
18. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy for resectable oesophageal cancer.
Eyck BM; van der Wilk BJ; Lagarde SM; Wijnhoven BPL; Valkema R; Spaander MCW; Nuyttens JJME; van der Gaast A; van Lanschot JJB
Best Pract Res Clin Gastroenterol; 2018; 36-37():37-44. PubMed ID: 30551855
[TBL] [Abstract][Full Text] [Related]
20. Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Petrillo A; Lorenzen S; van Laarhoven HWM
ESMO Open; 2022 Dec; 7(6):100613. PubMed ID: 36356415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
